Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Study Shows How Key HIV Protein Functions to Form Infectious Virus

A team of scientists at the Salk Institute and Rutgers University has determined the molecular structure of HIV Pol, a protein that plays a key role in the late stages of HIV replication, the process through which the virus propagates itself and spreads throug

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

A team of scientists at the Salk Institute and Rutgers University has determined the molecular structure of HIV Pol, a protein that plays a key role in the late stages of HIV replication, the process through which the virus propagates itself and spreads through the body. Importantly, determining the molecule’s structure helps answer longstanding questions about how the protein breaks itself apart to advance the replication process.

Understanding how HIV replicates within cells is key to developing new treatments that could help the nearly 40 million people globally who live with HIV. The new discovery reveals a new vulnerability in the virus that could be targeted with drugs. “Structure informs function, and the insights we gained from visualizing the molecular architecture of Pol give us a new understanding of the mechanism by which HIV replicates,” stated Dmitry Lyumkis, PhD, assistant professor in the Laboratory of Genetics and Hearst Foundation Developmental Chair at Salk. Lyumkis is co-senior author of the team’s published paper in Science, titled “Cryo-EM structure of HIV-1 Pol polyprotein provides insights into virion maturation.”

“Many of the gene products of RNA viruses are initially translated as precursor polyproteins that are subsequently cleaved to yield mature proteins that play either structural or enzymatic roles,” the investigators explained. Scientists previously knew that the HIV Pol polyprotein breaks into three enzymes—a protease (PR), a reverse transcriptase (RT) and an integrase (IN)—that work together to assemble the mature form of the virus.

The protease plays a critical role in initiating this process by chopping up the molecule to separate the other components. However, it was previously unknown how the protease itself breaks free, first from the larger polyprotein HIV Gag-Pol and then from HIV Pol, to accomplish this task. “In HIV-1, the structural proteins are translated initially as part

of Gag polyprotein, while the enzymes that enable the virus to multiply and spread are synthesized as part of the Gag-Pol precursor polyproteins,” the investigators noted in their published paper. “Both polyproteins are cleaved by the viral protease (PR), which is synthesized as part of Gag-Pol, during maturation.”

However, they further noted, relatively little is known about the molecular organization of the Pol portion of the Gag-Pol polyprotein or the immature forms of the viral enzymes. “This is due, at least in part, to the absence of systems that can be used to efficiently produce and purify large amounts of the HIV-1 Gag-Pol or Pol polyproteins for structural and other biophysical studies.”

The newly reported work suggests that the protease initiates the process by self-cleaving or cutting itself free from the rest of the molecule, aided by reverse transcriptase and, possibly, integrase.

For their study the team used cryogenic electron microscopy, an imaging technique to which Lyumkis has made important contributions, to reveal the three-dimensional structure of the HIV pol protein molecule. This led to the discovery that Pol is a dimer, meaning that it is formed by two proteins bound together. The finding was a surprise because other similar viral proteins are single-protein assemblies.

“The first challenge was producing a stable version of HIV Pol so the structure could be analyzed, which had never previously been reported,” says co-first author Jerry Joe Harrison, phD, senior lecturer at the University of Ghana. The authors noted, “We developed a system to produce stable HIV-1 Pol and determined its cryo–electron microscopy structure.” Co-senior author Eddy Arnold, PhD, board of governors professor and distinguished professor in the Center for Advanced Biotechnology and Medicine at Rutgers University, noted, “This was a key missing piece of the HIV structural puzzle.”

The group showed that in this two-sided structure, the protease component of Pol is “loosely tethered” to the reverse transcriptase component in a binding configuration that keeps the protease slightly flexible. “It’s holding the protease at arm’s length, loosely, and we believe that gives the protease a little bit of movement, which in turn allows it to initiate the cutting of polyproteins that is a prerequisite for viral maturation,” said co-first author Dario Passos, PhD, a former researcher in Lyumkis’ lab at Salk. “Current HIV treatments include multiple classes of inhibitors for all three enzymes, and the discovery also reveals a new vulnerability that could be targeted with drugs.”

“It was known (but not understood) that there is a coupling between these enzymes before HIV Pol breaks apart,” Commented Arnold. “Visualizing the HIV Pol structure explains the basis for this complex mechanism.”

The authors concluded in their paper, “ … our cryo-EM structure indicates that PR can form dimers while part of Pol … Together, our results show how HIV-1 maturation leverages the dimerization interface in the RT portion of Pol to regulate the maturation of polyprotein precursors.”

The authors say the discovery opens the door for important follow-up research, including studies of the structure of the larger and more complex polyprotein Gag-Pol, also involved in viral assembly, as well as taking a closer look at the role of integrase in assembling the mature form of the HIV virus during replication.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01How stable is the antibody?

A crucial question often addressed during preclinical development focuses on the in vivo stability of therapeutic antibodies. Increasing the half-life of a therapeutic antibody has several benefits ranging from higher treatment efficacy to increased advantages for the patients who will have a fewer number of therapy sessions and a reduced cost. Given these compelling benefits, following the identification of therapeutic antibodies with the desired specificity, developers usually subject them to a refinement step to increase their stability. This process is often hindered by the lack of reliable experimental tools to predict the half-life of antibodies in patients. The major hurdle of using mouse models to predict antibody stability in the serum lies in the way immunoglobulin proteins are processed by the organism. In mammals, most proteins circulating in the serum undergo constant uptake by endothelial cells and are routed through the endosomes to the lysosomal compartment for degradation. In the endosomes, immunoglobulin G (IgG) proteins are recognized and bound by a transmembrane protein, called the neonatal Fc receptor (FcRn), which mediates their recycling to the plasma membrane and subsequent release back into the serum. As a result, the half-life of IgGs are significantly extended by this mechanism. Since most therapeutic antibodies belong to the IgG class, this recycling system is very relevant for their relative stability in the body. Remarkably, the relative affinity between IgGs and FcRn is extremely disparate between different species, with the mouse receptor showing a much higher affinity than its human counterpart.

Source: www.genengnews.com ↗
02Undruggable or unscreenable?

Another obstacle to discovering new PPI inhibitors is the lack of libraries designed to hunt for them, points out Philippe Roche, PhD, senior scientist at the Integrative Structural and Chemical Biology team at the Cancer Research Center of Marseilles, France. “If you screen PPIs using libraries that were designed for kinases or GPCRs, that’s why you don’t get a lot of good results,” he says. To that end, his group began assembling a library focused on orthosteric inhibitors of PPIs. The result was 2P2Idb, a hand-curated, structural database cataloguing orthosteric inhibitors of PPIs for which the interface had been 3D characterized. From analyzing these known PPI inhibitors, and what structures they had in common, Roche and his colleagues developed a model to predict whether compounds would likely inhibit PPIs. Using this method, 2P2Idb creates an enriched screening library that dramatically increases the hit rate compared to standard libraries. Having proven their success with a small library of 1600 compounds, they are in the process of expanding the library to 10,000 compounds. Once that’s published, “the idea is to make this library available to labs around the world,” Roche says. “We will provide the library free of charge for people to be able to screen PPI targets.”

Source: www.genengnews.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →